Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock is listed on the Nasdaq Global Select Market and has traded under the symbol “AMPH” since our initial public offering on June 25, 2014. Prior to this date, there was no public market for our common stock.
Dividend Policy
We have not declared or paid any dividends on our common stock since our initial public offering. We currently anticipate that we will retain future earnings, if any, for the development, operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Additionally, our ability to pay dividends on our common stock is limited by restrictions under the terms of our existing credit facilities. Any future determinations related to dividend policy will be made at the discretion of our Board of Directors.
Holders of Record
At February 25, 2025, we had 47,650,121 shares of common stock outstanding held by approximately 116 stockholders of record of our common stock. We believe the actual number of stockholders is greater than this number of record holders, including stockholders who are beneficial owners but whose shares are held in “street” name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Stock Performance Graph
This graph shall not be deemed “soliciting material” or to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Amphastar Pharmaceuticals, Inc. under the Securities Act or the Exchange Act.
The following graph illustrates a comparison of the total cumulative stockholder return on our common stock since December 31, 2019, with the cumulative stockholder return since December 31, 2019, on two indices: the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes an initial investment of $100 on December 31, 2019, both in our common stock and each index. It also assumes reinvestment of dividends, if any. Historical stockholder return shown is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
81
Table of Contents
Issuer Purchases of Equity Securities During the Quarter Ended December 31, 2024
The table below provides information with respect to repurchases of our common stock.
Total Number of Shares
Maximum Number of
Average
Purchased as Part of
Shares that May Yet Be
Total Number of Shares
Price Paid
Publicly Announced Plans
Purchased Under the Plans
Period
Purchased (1)
per Share
or Programs
or Programs
October 1 - October 31, 2024
312,673
$
48.46
312,673
—
November 1 - November 30, 2024
291,557
46.27
291,557
—
December 1 - December 31, 2024
311,114
42.88
311,114
—
(1) On November 4, 2024, we announced that our Board of Directors authorized an increase of $50.0 million to our share buyback program. As of December 31, 2024, $50.0 million remained available for repurchase under such program. The share buyback program does not have an expiration date.
Recent Sales of Unregistered Securities
None.
Item 6. [Reserved]
82
Table of Contents